Recherche
-
Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
(BMJ open ophthalmology. vol. 4, n° 1, pp. e000185, 2019)Article de revueLibre accès -
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
(Advances in Therapy, 2020)Article de revueLibre accès -
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
(Ophthalmology and Therapy. vol. 13, n° 3, pp. 725-738, 2024-03-01)Article de revueLibre accès -
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
(The British Journal of Ophthalmology. vol. 105, n° 11, 2021-10-21)Article de revueLibre accès -
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
(Ophthalmology Retina. vol. 2, n° 10, pp. 988-996, 2018-10)Article de revueLibre accès -
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study
(American Journal of Ophthalmology, 2021-02-06)Article de revueLibre accès -
Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies
(Ophthalmology Retina. vol. 3, n° 8, pp. 663-669, 2019-08)Article de revueLibre accès -
Retinal microvasculature and incident dementia over 10 years: The Three-City-Alienor cohort
(Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. vol. 15, n° 4, pp. e12480, 2023-10)Article de revueLibre accès -
Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies
(Ophthalmology Retina. vol. 3, n° 7, pp. 553-560, 2019-07)Article de revueLibre accès -
Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study
(Graefe's Archive for Clinical and Experimental Ophthalmology. vol. 258, n° 3, pp. 521-528, 2020)Article de revueLibre accès